Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
12/11/2019 | 22:35 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:FLKS | Flex Pharma, Inc. |
28/10/2019 | 13:33 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:FLKS | Flex Pharma, Inc. |
28/10/2019 | 13:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:FLKS | Flex Pharma, Inc. |
18/09/2019 | 23:03 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:FLKS | Flex Pharma, Inc. |
18/09/2019 | 22:56 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
14/09/2019 | 00:32 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
14/09/2019 | 00:31 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
13/09/2019 | 12:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:FLKS | Flex Pharma, Inc. |
29/07/2019 | 23:28 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:FLKS | Flex Pharma, Inc. |
24/07/2019 | 01:54 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:FLKS | Flex Pharma, Inc. |
18/07/2019 | 23:06 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:FLKS | Flex Pharma, Inc. |
12/07/2019 | 22:05 | Business Wire | Flex Pharma Announces Approval of all Merger-Related Proposals at Special Meeting | NASDAQ:FLKS | Flex Pharma, Inc. |
27/06/2019 | 12:03 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:FLKS | Flex Pharma, Inc. |
25/06/2019 | 13:00 | Business Wire | Flex Pharma Announces Broker Authority to Vote on Certain Proposals | NASDAQ:FLKS | Flex Pharma, Inc. |
20/05/2019 | 12:02 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:FLKS | Flex Pharma, Inc. |
01/05/2019 | 13:00 | Business Wire | Flex Pharma Reports First Quarter 2019 Financial Results | NASDAQ:FLKS | Flex Pharma, Inc. |
29/04/2019 | 21:23 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:FLKS | Flex Pharma, Inc. |
24/04/2019 | 22:16 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:FLKS | Flex Pharma, Inc. |
18/04/2019 | 12:01 | Edgar (US Regulatory) | Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
16/04/2019 | 22:13 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
06/03/2019 | 23:09 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:FLKS | Flex Pharma, Inc. |
06/03/2019 | 22:14 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:FLKS | Flex Pharma, Inc. |
06/03/2019 | 13:00 | Business Wire | Flex Pharma Reports Fourth Quarter and Fiscal 2018 Financial Results | NASDAQ:FLKS | Flex Pharma, Inc. |
14/02/2019 | 12:22 | Edgar (US Regulatory) | Securities Registration: Business Combination (s-4) | NASDAQ:FLKS | Flex Pharma, Inc. |
12/02/2019 | 21:50 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:FLKS | Flex Pharma, Inc. |
05/02/2019 | 16:05 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:FLKS | Flex Pharma, Inc. |
04/01/2019 | 13:00 | Business Wire | Flex Pharma & Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Thera... | NASDAQ:FLKS | Flex Pharma, Inc. |
21/12/2018 | 23:17 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:FLKS | Flex Pharma, Inc. |
06/12/2018 | 09:30 | PR Newswire (US) | Asceneuron Appoints Dr. Thomas C. Wessel as Chief Medical Officer | NASDAQ:FLKS | Flex Pharma, Inc. |
05/11/2018 | 13:00 | Business Wire | Flex Pharma Reports Third Quarter 2018 Financial Results | NASDAQ:FLKS | Flex Pharma, Inc. |